While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data informing AS inclusion criteria of patients with Grade Group (GG) 2 prostate cancer in the MRI era. Here we evaluate patient outcomes from a MRI-screened AS-eligible cohort of FIR GG2 PCa receiving radical prostatectomy (RP).
Patients with prostate MRI, NCCN FIR GG2 PCa (PSA < 10 ng/mL, ≤ cT2a, < 50% core positivity), and no prior treatments who underwent RP from 2015 to 2023 were included from a prospectively maintained prostatectomy registry. Primary outcomes were adverse pathologic features (APF) at RP (GG3-5, ≥ pT3a, or pN1) and biochemical recurrence (BCR). Logistic regression and Cox regression identified factors associated with APF at RP and time to BCR, respectively.
Of 522 patients, 110 (21%) had APF at RP and 45 (9%) developed BCR with median follow up 2.4 years (IQR 1.3-2.8). On multivariable logistic regression, % Gleason pattern 4 (%GP4, %GP4 > 25% OR 2.14, 95% CI 1.28-3.58, p = 0.004) was independently associated with APF. On multivariable Cox regression for time to BCR, PSAD (HR 1.06, 95% CI 1.04-1.09, p < 0.001) and positive surgical margins (HR 1.06, 95% CI 1.09-3.78, p = 0.03) were independently associated with BCR. PIRADS, % core positivity, and specimen involvement were associated with neither APF nor BCR.
% Gleason pattern 4 > 25% and PSAD are the primary factors associated with adverse outcomes and should be considered for patients with FIR GG2 PCa considering active surveillance. PIRADS and measures of biopsy cancer volume were not associated with APF or BCR. These results may inform patient selection for active surveillance among patients with FIR GG2 PCa.
The Prostate. 2026 Jun 08 [Epub ahead of print]
Eric V Li, Eman E Ahmed, Mohamed E Ahmed, Michael K Wang, Julian Diaz-Cobo, Jamie O'Byrne, John C Cheville, Paras H Shah, Igor Frank, Matthew K Tollefson, Stephen A Boorjian, Vidit Sharma, Abhinav Khanna, R Jeffrey Karnes
Department of Urology, Mayo Clinic, Rochester, Minnesota, USA., Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA., Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.